Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 25, 2025
Daily News
September 25, 2025
- Japanese Pharma-Cosmetic Union Breaks from UA Zensen, Set to Join Rengo
September 25, 2025
- JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
September 25, 2025
- Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
- Australia Clears Leqembi after Tribunal Review
September 25, 2025
- Taiho Hooks Up with Guardant Health in Biomarker Search
September 25, 2025
- GE HealthCare to Develop Lantheus’ Prostate Cancer PET Agent in Japan
September 25, 2025
- Generic Use Rate at 89.6% in April: Payer
September 25, 2025
- Eisai Settles US Lenvima Suit with Dr. Reddy’s, Generic Launch Barred Until 2030
September 25, 2025
- Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer
September 25, 2025
- Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…